Mounjaro and Zepbound both contain tirzepatide, manufactured by Eli Lilly. Mounjaro received FDA approval in 2022 for type 2 diabetes management. Zepbound, approved in late 2023, is the same medication but branded specifically for chronic weight management. Both activate GLP-1 and GIP receptors (dual agonist), making them more potent than single-agonist GLP-1 medications like semaglutide. Clinical trials show tirzepatide produces 15-22% weight loss on average. The main distinction is marketing and FDA indication - Mounjaro for diabetes, Zepbound for obesity treatment.
Find a qualified GLP-1 provider
Compare pricing, clinical oversight, and patient reviews across verified telehealth programs and local clinics.
Compare Providers →Still have questions?
A qualified GLP-1 provider can give you personalized answers based on your medical history and goals.
Get answers to your GLP-1 questions
Weekly updates with the latest research, pricing changes, and expert guidance — delivered to your inbox.
No spam. Unsubscribe anytime.
Ready to start your GLP-1 journey?
Compare verified providers on pricing, medication sourcing, clinical oversight, and patient reviews — all in one place.